Sabiedrība ar ierobežotu atbildību "CentralPharma Communications"Active
Key figures
Ratios
2025Balance sheet structure
Summary of financial statements2010–2025
| 2010 | 2011 | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Balance sheet — assets | ||||||||||||||||
| Total current assets | 13 490 | 19 289 | 29 726 | 23 285 | 29 514 | 30 120 | 36 453 | 38 080 | 40 743 | 42 513 | 42 580 | 44 698 | 48 394 | 56 589 | 57 413 | 60 431 |
| Total non-current assets | 752 | 243 | 321 | 189 | 123 | 0 | 554 | 301 | 48 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Total assets | 14 242 | 19 532 | 30 047 | 23 474 | 29 637 | 30 120 | 37 007 | 38 381 | 40 791 | 42 513 | 42 580 | 44 698 | 48 394 | 56 589 | 57 413 | 60 431 |
| Balance sheet — liabilities and equity | ||||||||||||||||
| Current liabilities | 5778 | 6888 | 16 985 | 7183 | 5902 | 6081 | 12 686 | 12 983 | 9845 | 10 845 | 9995 | 11 810 | 14 977 | 23 017 | 23 581 | 26 433 |
| Non-current liabilities | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Total liabilities | 5778 | 6888 | 16 985 | 7183 | 5902 | 6081 | 12 686 | 12 983 | 9845 | 10 845 | 9995 | 11 810 | 14 977 | 23 017 | 23 581 | 26 433 |
| Share capital | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| Retained earnings of previous periods | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| Profit for the year | 2360 | 4180 | 417 | 3229 | 555 | 303 | 282 | 1077 | 1100 | 722 | 917 | 303 | 529 | 155 | 261 | 166 |
| Total equity | 8464 | 12 644 | 13 062 | 16 291 | 23 735 | 24 039 | 24 321 | 25 398 | 30 946 | 31 668 | 32 585 | 32 888 | 33 417 | 33 572 | 33 832 | 33 998 |
| Income statement | ||||||||||||||||
| Sales revenue | 111 699 | 80 499 | 89 508 | 72 804 | 134 176 | 115 792 | 163 915 | 179 185 | 160 447 | 155 490 | 127 400 | 149 830 | 165 120 | 217 810 | 295 390 | 268 900 |
| Operating profit | 2885 | 4997 | 514 | 4059 | 763 | 369 | 282 | 1287 | 1123 | 748 | 917 | 303 | 529 | 378 | 261 | 166 |
| Profit before income tax | 2885 | 4997 | 514 | 4059 | 763 | 369 | 282 | 1287 | 1123 | 748 | 917 | 303 | 529 | 378 | 261 | 166 |
| Profit for the reporting year | 2360 | 4180 | 417 | 3229 | 555 | 303 | 282 | 1077 | 1100 | 722 | 917 | 303 | 529 | 155 | 261 | 166 |
| Labour costs | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| Depreciation of non-current assets | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| Other indicators | ||||||||||||||||
| Employees | 4 | 4 | 4 | 4 | 4 | 4 | 3 | 3 | 3 | 3 | 3 | 3 | 4 | 5 | 5 | 5 |
| Calculated dividend | — | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
A dash (—) means the report has not been filed or the line is not reported; 0 is a zero stated in the report.
Connections graph
Summary: Sabiedrība ar ierobežotu atbildību "CentralPharma Communications"
Overview
Sabiedrība ar ierobežotu atbildību "CentralPharma Communications" (reg. no. 40003521795) is a limited liability company. The company was registered in 2000 and has been in the register for 25 years. Registered address: Rīga, Baložu iela 28 - 13.
Financial results
Revenue in 2025 was 268 900 €, down 9,0% on the previous year (295 390 €). From 2010 to 2025, revenue grew by an average of 6,0% per year. Net profit for 2025 was 166 € (0,1% of revenue). The company was profitable in all 16 published years. In 2025 the company had 5 employees. Revenue per employee was 53 780 €. At the end of 2025, total assets were 60 431 € and equity 33 998 € (56,3% of assets).
Management and owners
The company has one board member. The sole owner of the company is OU CentralPharma Communications.
Data sources and freshness
Register data (name, address, legal form, board and owners) and annual report figures come from the open data of the Register of Enterprises of the Republic of Latvia (CC0); entity.lv updates them daily. Data as of 03.11.2026. Changes, averages and ratios are calculated by entity.lv from open data and are not an official assessment.